Meeting
2024 ASCO Genitourinary Cancers Symposium
Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
Authors
Georges Gebrael
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Georges Gebrael , Yeonjung Jo , Umang Swami , Melissa Plets , Chadi Hage Chehade , Arshit Narang , Shilpa Gupta , Zin Myint , Nicolas Sayegh , Catherine Tangen , Maha H. A. Hussain , Tanya B. Dorff , Primo N Lara Jr., Seth P. Lerner , Ian M. Thompson Jr., Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT01809691
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 188)
DOI
10.1200/JCO.2024.42.4_suppl.188
Abstract #
188
Poster Bd #
H17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
First Author: Mamta Parikh
Poster
2023 ASCO Annual Meeting
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
First Author: Amir Goldkorn
Poster
2023 ASCO Annual Meeting
Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.
First Author: Nicolas Sayegh
Poster
2023 ASCO Annual Meeting
Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.
First Author: Primo N Lara Jr.